The size of the Latin America Superdisintegrants Market has been valued at USD 43.05 million in 2022. It is estimated to be growing at a CAGR of 7.93% and worth USD 63.05 million by 2027.
Increasing orally disintegrating tablets and blooming new super disintegrants from the pharmaceutical companies are boosting the market growth. Escalating the growth of heart-related diseases and neurological infections, enlargement of pharmaceutical industries market, and rising concentration on quick and orally disintegrating tablets accelerate market growth. Pharmaceutical industries focus on super disintegrants as there is an increase in miscibility of active pharmaceutical ingredients due to the growing adoption of the drug in the body. The availability of drugs also escalates, which augments the growing market demand because of the above factor. Augmenting the importance of new drug delivery approaches is expected to drive users' consciousness and attention to orally disintegrating tablets over the assumption period.
However, protection, security, and quality concerns related to the super disintegrants market are likely to impede the growth. The cost factor pertaining to the production of super disintegrants is estimated to obstruct market growth. The super disintegrants market growth is cramped due to drooping monetary support for the research and development activities.
This research report on the Latin America Superdisintegrants Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Area:
Based on the region, Brazil is leading the market while Argentina is in second place. Large population and increasing healthcare investments and health awareness among individuals have helped Brazil hold the market's major share.
Argentina is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure, and awareness and increasing excipient manufacturing outsourcing.
Noteworthy Companies leading the Latin America Superdisintegrants Market Profiled in the Report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co., and Huber Corporation.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]